Biological therapies directed at proinflammatory cytokines have irrevocably changed the
landscape of treatment of rheumatoid arthritis (RA) and other autoimmune diseases. With
the advances in our knowledge in cytokine signalling, the question emerges whether
targeting intracellular signalling might also be a safe and efficacious strategy. Janus kinases
or Jaks are critical for a large family of cytokines and the first Jak inhibitors has been
approved by the FDA. It is therefore timely to consider this new category of drugs and reflect …